AACR22 tackles the CAR T solid tumor challenge

Solid tumors are the next frontier for CAR T cell therapies, and researchers are using AACR22 to showcase new technologies to address the biggest obstacles to moving the modality beyond blood cancers.

Those hurdles include finding solid tumor-selective targets, addressing the heterogeneity of solid tumors, and overcoming the suppressive effects of the solid tumor microenvironment...